Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation
Background: The most common autoimmune blistering disease, bullous pemphigoid (BP), shows an increased prevalence in psoriatic patients and oncologic patients undergoing immune-checkpoint blockade (ICB). Even though the same autoantigens (BP180/BP230) are detectable, it remains obscure whether clini...
Saved in:
Main Authors: | Dennis Niebel (Author), Dagmar Wilsmann-Theis (Author), Thomas Bieber (Author), Mark Berneburg (Author), Joerg Wenzel (Author), Christine Braegelmann (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines
by: Dennis Niebel, et al.
Published: (2021) -
Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis
by: Sebastian Hoffmann, et al.
Published: (2018) -
Multirefractory bullous pemphigoid, psoriasis and psoriatic arthritis successfully treated with guselkumab
by: Francisco José Rodríguez-Cuadrado, et al.
Published: (2024) -
Association of bullous pemphigoid and Grover disease induced by immune checkpoint therapy
by: Elena Lucía Pinto-Pulido, et al.
Published: (2024) -
Superimposed effects of adalimumab and linagliptin on the development of bullous pemphigoid in a psoriatic patient: A case report
by: Katsuhiro Yamada, et al.
Published: (2021)